Skip to main content
. 2020 Jul 6;5:54. doi: 10.1038/s41541-020-0205-6

Table 2.

Seropositivity following full-dose yellow fever (YF) vaccination in children.

Study Vaccine Population Type Test and seropositivity criteria Time post vaccination Seropositive
No. (%)

López 201658

17D-204 (France)

Endemic RCT

PRNT50

Titer ≥10

1m 594/595 (99.8)

Chowdhury 2015a59

17DD (Brazil)Ghana

17D-213 (Russia)Mali

Endemic RCT

Micro-PRNT50

Titer ≥8

1m

841G

300M

(68–79)G

(95–98)M

Domingo 201934

17DD (Brazil)Ghana

17D-213 (Russia)Mali

Endemic RCT

Micro-PRNT90

≥0.5 IU/mLb

2.3y

4.5y

6y

121/436G

296/587M

188/436G

(28)G

(50)M

(43)G

De Noronha 2019c33 17DD (Brazil) Endemic Obs

Micro-PRNT50

Titer ≥10

0–6m

1y

2y

4y

7y

10y

143/165

107/140

97/136

72/122

57/135

58/126

(87)

(76)

(71)

(59)

(42)

(46)

G Ghana, M Mali, Obs observational, PRNT plaque reduction neutralization test, RCT randomized control trial, IU international units, m months, y years.

aNumbers represent the number of children with immunogenicity results included in the respective countries (denominator) and proportions represent those seroconverting; 64–68% of children in Ghana (N = 38) and 90–98% of children in Mali (n = 12) were seropositive at baseline and had ≥2-fold increase in antibody titer.

bData from vaccinees were also presented in the same paper using any detectable antibodies. The proportion of seropositive was higher for all groups: 39% (172/436) at 2.3 years in Ghana; 70% (409/587) seropositivity at 4.5 years in Mali; and 51% (223/436) seropositivity at 6 years in Ghana.

cSame data presented in Campi-Azevedo et al. (2019)55.